Our New York presenter recommended Cleveland BioLabs. This small biotech boasts an impressive pipeline, with the leading drug candidate potentialy offering a fast-acting antidot against radiation, a space where there are no effective treatments currently available. The company has partnerships with world-class research organizations, including Roswell Park Cancer Institute and Cleveland Clinic. As any small biotech, CBLI is a speculative play, but early test results show great potential. The company is also developing a family of anti-cancer agents.